Core Viewpoint - The company reported a significant increase in revenue and net profit for the year 2025, driven by strategic market initiatives and operational improvements [1][3]. Financial Performance - The company achieved total revenue of 223.51 million yuan, representing a year-on-year growth of 8.48% [1]. - The net profit attributable to the parent company was 13.15 million yuan, showing a remarkable increase of 203.86% compared to the previous year [1]. - Total assets at the end of the reporting period were 1.564 billion yuan, reflecting a growth of 1.64% from the beginning of the year [2]. - The equity attributable to the parent company was 1.433 billion yuan, up by 2.21% from the start of the year [2]. - The net asset value per share attributable to the parent company was 10.47 yuan, an increase of 1.13% [2]. Operational Factors - The orthopedic artificial bone procurement provided opportunities for continued clinical usage and market share expansion, prompting the company to enhance its production assurance system [3]. - The company implemented a refined regional market strategy and precise marketing tactics to broaden its sales network, contributing to steady revenue growth and reinforcing its leading position in niche markets [3]. - The increase in operating profit, total profit, and net profit attributable to the parent company exceeded 30%, primarily due to the procurement initiative and the recovery of long-term accounts receivable, which significantly reduced credit impairment losses [4].

Financial Performance Forecast - The company expects to achieve an operating revenue of approximately 223.51 million yuan for the year 2025, an increase of about 17.47 million yuan, representing a year-on-year growth of approximately 8.48%[5] - The net profit attributable to the parent company's shareholders is projected to be around 13.53 million yuan for 2025, an increase of approximately 26.19 million yuan, indicating a turnaround from loss to profit[5] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is expected to be around -0.92 million yuan, an improvement of approximately 27.46 million yuan compared to the previous year[5] - In 2024, the company reported an operating revenue of 206.03 million yuan and a net loss attributable to the parent company's shareholders of 12.66 million yuan[7] Factors Influencing Performance - The company attributes the performance improvement to the increased clinical usage of orthopedic artificial bone and the expansion of market share through enhanced production and marketing strategies[9] - The adjustment in the profit forecast is due to higher-than-expected asset impairment losses, leading to a decrease in the net profit after deducting non-recurring items from the previous estimate[10] Forecast Accuracy and Accountability - The company emphasizes that the forecast data is preliminary and has not been audited by an accounting firm, with no significant uncertainties affecting the accuracy of the forecast identified[12] - The board of directors has expressed sincere apologies for the discrepancies in the earnings forecast and commits to improving accounting practices to prevent similar issues in the future[14]

证券代码:688613 证券简称:奥精医疗 公告编号:2026-006 奥精医疗科技股份有限公司 2025年年度业绩预告更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）前次业绩预告情况 公司于2026年1月29日披露了《2025 年年度业绩预告》（2026-004），预计 情况如下： 经奥精医疗科技股份有限公司（以下简称"公司"）财务部门初步测算： 1、预计2025年年度实现营业收入为22,350.56万元左右，与上年同期（法 定披露数据）相比，预计将增加1,747.26万元左右，同比增加8.48%左右。 2、预计2025年年度实现归属于母公司所有者的净利润为1,353.17万元左右， 与上年同期相比，预计将增加2,619.38万元左右，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净利润 为-51.47万元左右，与上年同期相比，预计将增加2,785.64万元左右。 3、预计2025年年度 ...

Group 1 - The core viewpoint of the article is that Aojing Medical reported a significant increase in both revenue and net profit for the year 2025, indicating strong financial performance [2] Group 2 - Aojing Medical achieved total operating revenue of 223.51 million yuan in 2025, representing a year-on-year growth of 8.48% [2] - The net profit attributable to the parent company was 13.15 million yuan, showing a remarkable year-on-year increase of 203.86% [2]

Core Viewpoint - Aojing Medical (688613.SH) reported a revenue of 224 million yuan for the year 2025, marking an 8.48% year-on-year growth, and achieved a net profit of 13.15 million yuan, turning from loss to profit [1] Group 1: Financial Performance - The total operating revenue for 2025 reached 224 million yuan, reflecting an 8.48% increase compared to the previous year [1] - The net profit attributable to the parent company was 13.15 million yuan, indicating a turnaround from previous losses [1] Group 2: Factors Influencing Performance - The orthopedic artificial bone procurement provided opportunities for clinical usage to continue increasing and further expand market share [1] - The company strengthened its production guarantee system to ensure stable fulfillment of the increased demand resulting from procurement [1] Group 3: Marketing Strategy - The company continued to deepen its regional market strategy through refined management and precise marketing tactics, consistently broadening its sales network [1] - The overall revenue growth demonstrated a steady upward trend, further solidifying the company's leading position in the niche market [1]

Core Viewpoint - Aojing Medical (688613.SH) reported a total operating revenue of 224 million yuan for the year 2025, representing a year-on-year growth of 8.48%, and achieved a net profit attributable to the parent company of 13.15 million yuan, marking a turnaround from loss to profit [1] Group 1: Financial Performance - The company achieved total operating revenue of 224 million yuan in 2025, reflecting an 8.48% increase compared to the previous year [1] - The net profit attributable to the parent company was 13.15 million yuan, indicating a successful turnaround from a loss [1] Group 2: Factors Influencing Performance - The growth in operating performance was primarily driven by the orthopedic artificial bone procurement, which provided opportunities for increased clinical usage and market share expansion [1] - The company strengthened its production assurance system to meet the increased demand resulting from the procurement [1] Group 3: Marketing Strategy - The company continued to deepen its regional market strategy through refined management and targeted marketing strategies, which helped to expand its sales network [1] - The overall operating revenue showed a steady growth trend, further consolidating the company's leading position in the niche market [1]

Financial Performance - The company achieved total operating revenue of 223.51 million yuan, a year-on-year increase of 8.48%[2] - Net profit attributable to shareholders of the parent company reached 13.15 million yuan, a significant increase of 203.86% compared to the previous year[2] - The total assets at the end of the reporting period were 1,564.45 million yuan, reflecting a growth of 1.64% from the beginning of the period[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was -0.915 million yuan, an improvement of 96.77% year-on-year[4] - The company’s basic earnings per share was 0.10 yuan, compared to -0.09 yuan in the previous year, marking a 207.03% increase[2] - The weighted average return on net assets increased by 1.84 percentage points to 0.93%[2] Operational Strategy - The company strengthened its production guarantee system to meet the increased demand from orthopedic artificial bone procurement[5] - The marketing strategy focused on regional market development and precise marketing, contributing to steady revenue growth[5] - The significant increase in operating profit and total profit was attributed to the recovery of long accounts receivable due to extended credit terms for distributors[7] Financial Data Disclaimer - Investors are advised to note that the financial data for 2025 is preliminary and unaudited, with final results to be confirmed in the annual report[8]

Core Viewpoint - Aojing Medical (688613.SH) reported a strong performance in its 2025 annual earnings, with significant growth in both revenue and net profit, driven by strategic market initiatives and enhanced production capabilities [1] Financial Performance - The company achieved total operating revenue of 223.51 million yuan, representing a year-on-year increase of 8.48% [1] - The net profit attributable to the parent company was 13.15 million yuan, showing a remarkable year-on-year growth of 203.86% [1] Market Strategy - The orthopedic artificial bone procurement has provided the company with opportunities for continued clinical usage and further market share expansion [1] - The company has strengthened its production assurance system to reliably meet the increased demand resulting from procurement [1] - Aojing Medical has deepened its regional market strategy through refined management and targeted marketing strategies, continuously expanding its sales network [1] Market Position - The company's annual revenue demonstrates a steady growth trend, further consolidating its leading position in the niche market [1]

Core Viewpoint - The company reported a total operating revenue of 224 million yuan for 2025, reflecting a year-on-year growth of 8.48% [1] - The net profit attributable to the parent company reached 13.15 million yuan, showing a significant increase of 203.86% compared to the previous year [1] Financial Performance - Total assets at the end of the reporting period amounted to 1.564 billion yuan, which is a growth of 1.64% from the beginning of the year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -915,000 yuan, marking a year-on-year increase of 96.77% [1]

Company Overview - The closing price of Aojing Medical (688613.SH) on February 12, 2026, was 23.98 yuan, with a daily decline of 3.54% and a trading volume of 1.10 billion yuan, indicating a turnover rate of 3.31% [1] - As of February 12, the company's price-to-earnings ratio (TTM) was -910.15 times, and the price-to-book ratio was 2.29 times. The revenue forecast for 2025 is 224 million yuan, with a net profit attributable to the parent company of 13.53 million yuan, although the non-recurring net profit is expected to be a loss of 510,000 yuan [3] Industry Analysis - The medical device sector has seen a cumulative decline of 5.39% over the past 20 days, reflecting overall weak performance. Concerns regarding the continuity of medical procurement policies and increased risk aversion ahead of the long holiday have put pressure on small and medium-sized pharmaceutical stocks [4] Market Activity - On February 10, the stock price surged by 5.13% to 25.41 yuan, reaching a new high for the period. The subsequent decline on February 12 is viewed as a technical correction following a significant short-term increase [5] - The financing activity showed a recent trend of increased activity followed by a decline, with a net buy of 9.29 million yuan on February 10, but a net outflow of 7.63 million yuan on February 11, leading to a financing balance of 227 million yuan on February 12. The net outflow of main funds on February 12 indicates a profit-taking pressure from retail investors, who accounted for 38% of the inflow [2]